The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25 ...

The opinion is based on positive data from the phase 3 Balance study, which showed a significant reduction of triglycerides ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

"Gilead wins positive European approval opinion for twice-yearly HIV injection" was originally created and published by ...

The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

This page provides an overview of the opinions adopted at the January 2014 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes. Six new medicines ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease PR Newswire TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 ...

LONDON, Oct. 23, 2008-On 23 October 2008 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion** to recommend the variation to the terms of the marketing ...

Committee for Medicinal Products for Human Use Summary of Positive Opinion for Optaflu LONDON, April 26, 2007-On 26 April 2007 the Committee for Medicinal Products for Human Use (CHMP) adopted a ...

The Committee adopted positive opinions recommending the granting of marketing authorisations for the following new medicines: Eliquis (apixaban), from Bristol-Myers Squibb/Pfizer EEIG, intended ...